AI Article Synopsis
- Pim Kinases (Pim-1, Pim-2, and Pim-3) are active kinases involved in cell survival, proliferation, and migration, traditionally thought to be redundant but now recognized for distinct functions.
- While primarily linked to cancer progression, evidence suggests that Pim kinases also play significant roles in cardiovascular diseases, affecting inflammation, thrombosis, and cardiac injury.
- Targeting Pim kinases could offer a multi-targeted therapeutic strategy for treating cardiovascular diseases and their risk factors, warranting further exploration of their expression and activity in cardiovascular cells.
Article Abstract
Pim Kinases; Pim-1, Pim-2, and Pim-3, are a family of constitutively active serine/threonine kinases, widely associated with cell survival, proliferation, and migration. Historically considered to be functionally redundant, independent roles for the individual isoforms have been described. Whilst most established for their role in cancer progression, there is increasing evidence for wider pathological roles of Pim kinases within the context of cardiovascular disease, including inflammation, thrombosis, and cardiac injury. The Pim kinase isoforms have widespread expression in cardiovascular tissues, including the heart, coronary artery, aorta, and blood, and have been demonstrated to be upregulated in several co-morbidities/risk factors for cardiovascular disease. Pim kinase inhibition may thus be a desirable therapeutic for a multi-targeted approach to treat cardiovascular disease and some of the associated risk factors. In this review, we discuss what is known about Pim kinase expression and activity in cells of the cardiovascular system, identify areas where the role of Pim kinase has yet to be fully explored and characterised and review the suitability of targeting Pim kinase for the prevention and treatment of cardiovascular events in high-risk individuals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380471 | PMC |
| http://dx.doi.org/10.3390/ijms241411582 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Human PIM Kinase Inhibitors as a Class of Anthelmintic Drugs to Treat Intestinal Nematode Infections.
ACS Infect Dis
January 2025
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri 63110, United States.
Soil-transmitted helminth (STH) infections affect one-fourth of the global population and pose a significant threat to human and animal health, with limited treatment options and emerging drug resistance. (whipworm) stands out as a neglected disease, necessitating new drugs to address this unmet medical need. We discovered that several different chemical series of related human Provirus Integration sites for Moloney murine leukemia virus (PIM) family kinase inhibitors possess potent anthelmintic activity by using whole-worm motility assays.
View Article and Find Full Text PDFNew antiplatelet approach: inhibiting Pim kinase to reduce constitutive surface expression of thromboxane A receptor.
J Thromb Haemost
January 2025
Systems Pharmacology and Translational Therapeutics Laboratory, at the Center for Advanced Studies and Technology (CAST), and Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University Medical School, Chieti, Italy.
Constitutive surface expression of the thromboxane A2 receptor is Pim kinase-dependent.
J Thromb Haemost
January 2025
Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom; Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom. Electronic address:
Background: The thromboxane A2 receptor (TPαR) plays an important role in the amplification of platelet responses during thrombosis. Receptor activity is regulated by internalization and receptor desensitization. The mechanism by which constitutive surface expression of the TPαR is regulated is unknown.
View Article and Find Full Text PDFPIM2 inhibition promotes MCL1 dependency in plasma cells involving integrated stress response-driven NOXA expression.
Nat Commun
January 2025
Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, F-35043, Rennes, France.
Our study explores the complex dynamics of the integrated stress response (ISR) axis, highlighting PIM2 kinase's critical role and its interaction with the BCL2 protein family, uncovering key mechanisms of cell survival and tumor progression. Elevated PIM2 expression, a marker of various cancers, often correlates with disease aggressiveness. Using a model of normal and malignant plasma cells, we show that inhibiting PIM2 kinase inhibits phosphorylated BAD production and activates ISR-mediated NOXA expression.
View Article and Find Full Text PDFPIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis.
Theranostics
January 2025
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Shandong, China.
Article Synopsis
- Endothelial-to-mesenchymal transition (EndMT) is a process where endothelial cells transform into a different cell type, contributing to the dysfunction that initiates atherosclerosis, but the exact triggers in atherosclerotic environments are not well understood.
- Research involving single-cell sequencing in mice on a high-fat diet showed that PIM1, a protein, is expressed in both endothelial cells and atherosclerotic lesions and plays a crucial role in the progression of atherosclerosis.
- Knockdown of PIM1 in endothelial cells reduced atherosclerosis and EndMT by affecting key proteins and pathways associated with cell transformation, suggesting that targeting this pathway could be a potential therapeutic approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!